All Texas Biomedical Research Institute articles
-
NewsLow-dose cannabis compound reduces side effects of HIV treatment
Long-term, low doses of THC mitigate many harmful side effects and inflammation caused by HIV and antiretroviral therapy (ART). Benefits included increased production of serotonin, while inflammation, cholesterol and harmful secondary bile acids were all reduced.
-
NewsMalaria vaccine mimics natural immunity with high precision
A detailed analysis reveals one of the reasons why the R21/Matrix-M malaria vaccine works so well: the antibodies generated following vaccination are indistinguishable from those found in people who have been infected by the parasites.
-
NewsCritical step in COVID viral infection identified
Researchers have uncovered a mechanism that SARS-CoV-2, the virus that causes COVID-19, uses to protect itself inside the body as it works to replicate and infect more cells. Without this protective mechanism, viral infection is dramatically reduced.
-
NewsTB vaccine candidate provides ‘elite’ protection
A tuberculosis vaccine candidate under development shows complete protection and superior immune response in nonhuman primates compared to the existing BCG vaccine.
-
NewsBird flu is mutating - but antivirals still work
Researchers have identified nine mutations in a bird flu strain from a person in Texas. The bad news: this strain is more capable of causing disease and replicates better in the brain. Good news: approved antivirals are still effective.
-
NewsStudy traces Ebola’s route to the skin surface
Researchers have traced a cellular route the Ebola virus uses to traverse the inner and outer layers of skin and emerge onto the skin’s surface. The study identifies new cell types within the skin that are targeted by EBOV during infection.
-
News‘Unbreakable’ Lassa vaccine shows promising results
A live-attenuated vaccine candidate against Lassa virus completely protected guinea pigs exposed to an otherwise lethal dose of the virus, researchers have reported.
-
NewsPromising TB therapy safe for patients with HIV
A therapy showing promise to help control tuberculosis (TB) does not interfere with combined antiretroviral therapy (cART), according to new research.
-
NewsResearchers to develop a new method for preserving microbial samples
The project aims to develop a new method for preserving microbial samples without refrigeration/cooling requirements through integrating innovations in microfluidics, biomaterials, protein engineering, and synthetic biology.
-
NewsResearchers take step toward development of universal COVID-19 antibodies
Scientists have developed a promising new human monoclonal antibody that appears a step closer to a universal antibody cocktail that works against all strains of SARS-CoV-2.
-
NewsZika vaccine safe, effective when administered during pregnancy
A vaccine against Zika virus is safe and effective when administered both before and during pregnancy, according to new research.
-
NewsScientists discover Ebola virus uses tunnelling nanotubes to infect cells
A new study indicates that Ebola virus creates and uses intercellular tunnels to move from cell to cell within the human body and evade treatments.
-
NewsCancer therapy shows promise against tuberculosis
A promising new cancer therapy also appears extremely potent against one of the world’s most devastating infectious diseases: tuberculosis (TB).
-
NewsTexas Biomed partners with Scancell to test novel COVID vaccine
A DNA-based vaccine is very effective at protecting against COVID-19, according to a joint preclinical study by Scancell Ltd and Texas Biomedical Research Institute (Texas Biomed).
-
NewsSecond gene implicated in malaria chloroquine resistance evolution
How malaria parasites evolved to evade a major antimalarial drug has long been thought to involve only one key gene. Now, scientists have shown a second key gene is also involved in malaria’s resistance to the drug chloroquine.
-
NewsHIV vaccine candidate aims to block virus before it takes root
The National Institutes of Health has awarded $3.8 million to Texas Biomedical Research Institute to further develop a promising HIV vaccine candidate that stops the virus upon entry, before it begins rapidly spreading throughout the body.